Net margin is calculated as Net Income divided by its Revenue. Aroa Biosurgery's Net Income for the
six
months ended in Mar. 2026 was A$5.04 Mil. Aroa Biosurgery's Revenue for the
six
months ended in Mar. 2026 was A$47.49 Mil. Therefore, Aroa Biosurgery's net margin for the quarter that ended in Mar. 2026 was 10.62%.
The historical rank and industry rank for Aroa Biosurgery's Net Margin % or its related term are showing as below:
ASX:ARX'
s Net Margin % Range Over the Past 10 Years
Min: -85.98 Med: -9.95 Max: 4.5
Current: 4.5
ASX:ARX's Net Margin % is ranked better than 55.57% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs ASX:ARX: 4.50
Aroa Biosurgery (ASX:ARX) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Aroa Biosurgery Net Margin % Related Terms
Aroa Biosurgery Net Margin % Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aroa Biosurgery's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Net Margin % distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery (ASX:ARX) has a Net Margin % of 10.62% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Aroa Biosurgery and its competitors. According to the industry distribution chart, Aroa Biosurgery ranks #363 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 44.4%.
Is Aroa Biosurgery's Net Margin % too high?
Aroa Biosurgery's current Net Margin % is 10.62%. The Medical Devices & Instruments industry median Net Margin % is 2.09. Aroa Biosurgery's value of 10.62% is 408.1% above this industry median. Based on the distribution chart, Aroa Biosurgery ranks #363 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aroa Biosurgery has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #363 out of 817 companies for Net Margin %. This puts Aroa Biosurgery in the upper half of its industry. The industry median Net Margin % is 2.09. Aroa Biosurgery's value of 10.62% is 408.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current Net Margin % of 10.62% is 408.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current Net Margin % is 10.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.59 — trading 26.3% below its estimated fair value. The current Net Margin % is 10.62% and 408.1% above the Medical Devices & Instruments industry median of 2.09. Aroa Biosurgery's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Net Margin % is 10.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.59 is trading 26.3% below its estimated GF Value™ of A$0.80.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for ASX:ARX:
Net Margin %: 10.62%
GF Value™: A$0.80 vs. price of A$0.59 (26.3% below fair value)
Industry Position: 408.1% above the Medical Devices & Instruments median (#363 of 817)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
62GF Score
Get the complete analysis for ASX:ARX
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
